Antonio Rescifina
Overview
Explore the profile of Antonio Rescifina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
1243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomarchio E, Zagni C, Dattilo S, Vitiello L, Fuochi V, Furnari S, et al.
Carbohydr Polym
. 2025 Mar;
356:123412.
PMID: 40049981
Vulvovaginal candidiasis (VVC) affects a significant proportion of women during reproductive years, with recurrent infections posing a considerable therapeutic challenge. Conventional treatments, such as clotrimazole (Clo) administration, often require frequent...
2.
Pennisi R, Gentile D, Trischitta P, Barreca D, Rescifina A, Mandalari G, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004129
Since the onset of the COVID-19 (COronaVIrus Disease 19) pandemic, SARS-CoV-2 has exhibited a high transmission rate, further enhanced by new variants able to better adapt to humans. Addressing this...
3.
Saccullo E, Patamia V, Bifarella A, Ferlazzo A, Fiorenza R, Spitaleri L, et al.
Int J Biol Macromol
. 2025 Feb;
304(Pt 1):140695.
PMID: 39914552
In this study, we developed a sustainable nanocatalyst, AXFe, by functionalizing magnetite nanoparticles with an alginate-xanthine conjugate (AX). This hybrid material combines magnetite's adsorption and photocatalytic properties with the CO...
4.
Cosentino G, Dichiara M, Costanzo G, Coco A, Pasquinucci L, Marrazzo A, et al.
ChemMedChem
. 2025 Jan;
:e202401015.
PMID: 39887934
This study presents a series of tetrahydropyrrolo[3,4-c]pyrazole-based compounds designed as sigma-1 receptor (S1R) ligands, focusing on optimizing affinity and reducing off-target effects. We synthesized various derivatives from commercially available precursors...
5.
Vecchio M, Chiaramonte R, Buccheri E, Tomasello S, Leonforte P, Rescifina A, et al.
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860498
: The evolution of technology has continuously redefined the landscape of rehabilitation medicine. Researchers have long incorporated virtual reality (VR) as a promising intervention, providing immersive therapeutic environments for patients....
6.
Buccheri R, Coco A, Pasquinucci L, Amata E, Marrazzo A, Rescifina A
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859564
Precise binding free-energy predictions for ligands targeting metalloproteins, especially zinc-containing histone deacetylase (HDAC) enzymes, require specialized computational approaches due to the unique interactions at metal-binding sites. This study evaluates a...
7.
Costanzo G, Cosentino G, Grasso M, Patamia V, Zuccala S, Coco A, et al.
RSC Med Chem
. 2025 Jan;
PMID: 39777289
Inflammatory pain represents one of the unmet clinical needs for patients, as conventional therapies cause several side effects. Recently, new targets involved in inflammatory pain modulation have been identified, including...
8.
Saccullo E, Patamia V, Tomarchio E, Zagni C, Floresta G, Rescifina A
Bioorg Chem
. 2025 Jan;
155():108115.
PMID: 39756200
Positron Emission Tomography (PET) has emerged as a powerful imaging technique in molecular medicine, enabling the non-invasive visualisation and quantification of biological processes at the molecular level. Antibody-based PET imaging...
9.
Costanzo G, Coco A, Cosentino G, Patamia V, Parenti C, Amata E, et al.
Chem Biol Drug Des
. 2024 Dec;
104(6):e70037.
PMID: 39726303
Suitable structural modifications of the functional groups at N-substituent of (-)-cis-N-normetazocine nucleus modulate the affinity and activity profile of related ligands toward opioid receptors. Our research group has developed several...
10.
Fuochi V, Furnari S, Floresta G, Patamia V, Zagni C, Drago F, et al.
Arch Pharm (Weinheim)
. 2024 Nov;
358(1):e2400545.
PMID: 39520338
As the world transitions from the acute phase of the COVID-19 pandemic caused by SARS-CoV-2, the scientific community continues to explore various therapeutic avenues to control its spread and mitigate...